[go: up one dir, main page]

AU7045291A - Novel oxidized lipoproteins and methods for their preparation - Google Patents

Novel oxidized lipoproteins and methods for their preparation

Info

Publication number
AU7045291A
AU7045291A AU70452/91A AU7045291A AU7045291A AU 7045291 A AU7045291 A AU 7045291A AU 70452/91 A AU70452/91 A AU 70452/91A AU 7045291 A AU7045291 A AU 7045291A AU 7045291 A AU7045291 A AU 7045291A
Authority
AU
Australia
Prior art keywords
lipoproteins
low density
oxidized
density lipoprotein
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU70452/91A
Other languages
English (en)
Inventor
Eric T. Fossel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc filed Critical Beth Israel Deaconess Medical Center Inc
Publication of AU7045291A publication Critical patent/AU7045291A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lighting Device Outwards From Vehicle And Optical Signal (AREA)
  • Peptides Or Proteins (AREA)
AU70452/91A 1989-10-06 1990-10-04 Novel oxidized lipoproteins and methods for their preparation Abandoned AU7045291A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41838289A 1989-10-06 1989-10-06
US418382 1989-10-06

Publications (1)

Publication Number Publication Date
AU7045291A true AU7045291A (en) 1991-05-16

Family

ID=23657894

Family Applications (2)

Application Number Title Priority Date Filing Date
AU70400/91A Abandoned AU7040091A (en) 1989-10-06 1990-10-04 Methods and apparatus for treating disease states using oxidized lipoproteins
AU70452/91A Abandoned AU7045291A (en) 1989-10-06 1990-10-04 Novel oxidized lipoproteins and methods for their preparation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU70400/91A Abandoned AU7040091A (en) 1989-10-06 1990-10-04 Methods and apparatus for treating disease states using oxidized lipoproteins

Country Status (7)

Country Link
EP (2) EP0495014A4 (pt)
JP (2) JPH05500963A (pt)
AU (2) AU7040091A (pt)
BR (2) BR9007725A (pt)
CA (2) CA2067364A1 (pt)
FI (2) FI921431L (pt)
WO (2) WO1991004744A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023302A1 (en) * 1993-04-07 1994-10-13 The Australian National University Immunological assay of oxidatively modified human low density lipoproteins in plasma

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2674753B1 (fr) * 1991-04-02 1995-03-10 Jean Berque Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables.
PT1328289E (pt) * 2000-10-20 2008-12-10 Hamburger Stiftung Zur Foerder Proteínas oxidadas e sua actividade biológica e terapêutica, assim como sua utilização em diagnóstico através da inibição da interacção entre as proteínas oxidadas e cd36
BR0318274A (pt) * 2003-04-25 2006-05-23 Hamburger Stiftung Zur F Rderu combate de infecções do vìrus hi
WO2006059082A1 (en) * 2004-11-30 2006-06-08 Trigen Limited Oxidised lipids as reversal agents for boronic acid drugs
US9551768B2 (en) 2013-03-15 2017-01-24 East Carolina University NMR method for monitoring changes in the core of lipoprotein particles in metabolism and disease
US10775458B2 (en) 2018-03-05 2020-09-15 Texas Tech University System Method and system for non-invasive measurement of metabolic health

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2095338A (en) * 1927-08-20 1937-10-12 Ig Farbenindustrie Ag Process for oxidizing organic substances in the liquid phase and apparatus therefor
US2095388A (en) * 1935-08-03 1937-10-12 Bendix Radio Corp Electrical regulator apparatus
US3655700A (en) * 1970-02-02 1972-04-11 Zoecon Corp Oxygenated unsaturated aliphatic carboxylic acids and esters
US4226713A (en) * 1978-04-24 1980-10-07 Goldberg Jack M Diagnostic agents
JPS5810056A (ja) * 1981-07-10 1983-01-20 株式会社クラレ 血液浄化装置
DD243714A1 (de) * 1985-10-08 1987-03-11 Akad Wissenschaften Ddr Verfahren zur stabilisierung von immobilisierter glukoseoxidase

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023302A1 (en) * 1993-04-07 1994-10-13 The Australian National University Immunological assay of oxidatively modified human low density lipoproteins in plasma

Also Published As

Publication number Publication date
FI921430A7 (fi) 1992-04-01
FI921430A0 (fi) 1992-04-01
WO1991005536A2 (en) 1991-05-02
EP0494992A1 (en) 1992-07-22
CA2067364A1 (en) 1991-04-07
WO1991004744A1 (en) 1991-04-18
AU7040091A (en) 1991-04-28
FI921431A0 (fi) 1992-04-01
EP0495014A4 (en) 1993-07-28
JPH05500963A (ja) 1993-02-25
BR9007721A (pt) 1992-08-18
EP0495014A1 (en) 1992-07-22
WO1991005536A3 (en) 1991-08-08
CA2067356A1 (en) 1991-04-07
FI921431A7 (fi) 1992-04-01
EP0494992A4 (en) 1993-03-31
BR9007725A (pt) 1992-08-18
JPH05501258A (ja) 1993-03-11
FI921431L (fi) 1992-04-01
FI921430L (fi) 1992-04-01

Similar Documents

Publication Publication Date Title
US5192264A (en) Methods and apparatus for treating disease states using oxidized lipoproteins
JP6806830B2 (ja) Ｐｕｆａ誘導体による酸化ストレス障害の緩和
Schafer et al. Comparing β-carotene, vitamin E and nitric oxide as membrane antioxidants
Wagner et al. The oxidation of blood plasma and low density lipoprotein components by chemically generated singlet oxygen.
JP4316878B2 (ja) 環状サレン−金属化合物：疾患の処置及び予防において抗酸化剤として有用な反応性酸素種スカベンジャー
JPH08501301A (ja) 血液における感光剤の皮膚を通しての生体内活性化
US5366440A (en) Methods for treating disease states using oxidized lipoproteins in conjunction with chemotherapeutic effector agents
AU7045291A (en) Novel oxidized lipoproteins and methods for their preparation
EP1181026B1 (en) Improved method for treating mammals with modified mammalian blood
Wills et al. The formation of peroxides in tissue lipids and unsaturated fatty acids by irradiation
Burlakova et al. Hybrid antioxidants
Bocci How does ozone act? How and why can we avoid ozone toxicity?
US5217716A (en) Method for treating viral infections using oxidized lipoproteins
JP2001026536A (ja) ラジカルスカベンジャー
Rakovsky et al. Application of ozone in medicine
Pintar et al. Bleaching of membrane-bound merocyanine 540 in conjunction with free radical-mediated lipid peroxidation
Serezhenkov et al. Antidiabetes drug metformin is a donor of nitric oxide: EPR measurement of efficiency
Vargas et al. Formation of a perbenzoic acid derivative in the photodegradation of fenofibrate: phototoxicity studies on erythrocytes
Yoshikawa Free radicals and hyperthermia in the treatment of cancer
WO1992001467A1 (en) Method for treating viral infections using oxidized lipoproteins
Lee The antioxidant and antiatherogenic effects of MAK-4 in WHHL rabbits
Nogala-Kalucka et al. 3 Free Radicals in Biological
Toda Ultrastructural study of malonaldehyde-induced arterial lesions in chickens
Wozniak et al. The effect of ascorbic acid and ethanol on the level of thiobarbituric acid reactive substances (TBARS) in selected tissues of albino BALB/c mice
Bugaj et al. Photostability of lipid components of human blood plasma lipoproteins during exposure to long wave ultraviolet radiation (UV-A) alone and in the presence of 8-methoxypsoralen